首页> 美国卫生研究院文献>Acta Crystallographica Section F: Structural Biology and Crystallization Communications >Crystallization and preliminary X-ray diffraction analysis of Val57 mutants of the amyloidogenic protein human cystatin C
【2h】

Crystallization and preliminary X-ray diffraction analysis of Val57 mutants of the amyloidogenic protein human cystatin C

机译:淀粉样蛋白原人类半胱氨酸蛋白酶抑制剂C的Val57突变体的结晶和初步X射线衍射分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Human cystatin C (hCC) is a low-molecular-mass protein (120 amino-acid residues, 13 343 Da) found in all nucleated cells. Its main physiological role is regulation of the activity of cysteine proteases. Biologically active hCC is a monomeric protein, but all crystallization efforts have resulted in a dimeric domain-swapped structure. Recently, two monomeric structures were reported for cystatin C variants. In one of them stabilization was achieved by abolishing the possibility of domain swapping by the introduction of an additional disulfide bridge connecting the two protein domains (Cys47–Cys69). In the second structure, reported by this group, the monomeric hCC fold was preserved by stabilization of the conformationally constrained loop (L1) by a single-amino-acid substitution (V57N). To further assess the influence of changes in the sequence and properties of loop L1 on the dimerization propensity of cystatin C, two additional hCC mutants were obtained: one with a residue favoured in β-­turns (V57D) and another with proline (V57P), a residue that is known to be a structural element that can rigidify but also broaden turns. Here, the expression, purification and crystallization of V57D and V57P variants of recombinant human cystatin C are described. Crystals were grown by the vapour-diffusion method. Several diffraction data sets were collected using a synchrotron source at the Advanced Photon Source, Argonne National Laboratory, Chicago, USA.
机译:人胱抑素C(hCC)是一种在所有有核细胞中发现的低分子蛋白质(120个氨基酸残基,13 343 Da)。它的主要生理作用是调节半胱氨酸蛋白酶的活性。具有生物活性的hCC是一种单体蛋白,但是所有的结晶努力都导致了二聚结构域交换结构。最近,报道了半胱氨酸蛋白酶抑制剂C变体的两个单体结构。其中之一是通过引入连接两个蛋白质结构域(Cys47–Cys69)的附加二硫键消除了结构域交换的可能性,从而实现了稳定。在该小组报告的第二种结构中,单体hCC折叠通过单氨基酸取代(V57N)稳定构象约束环(L1)得以保留。为了进一步评估环L1的序列和特性变化对半胱氨酸蛋白酶抑制剂C的二聚化倾向的影响,还获得了另外两个hCC突变体:一个突变体带有一个β-turns残基(V57D),另一个带有脯氨酸(V57P),残留物,已知是可以硬化但又可以加宽匝数的结构元素。在此,描述了重组人胱抑素C的V57D和V57P变体的表达,纯化和结晶。通过蒸气扩散法生长晶体。在美国芝加哥阿贡国家实验室的高级光子源中,使用同步加速器源收集了一些衍射数据集。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号